Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 99 EP593 | DOI: 10.1530/endoabs.99.EP593

ECE2024 Eposter Presentations Adrenal and Cardiovascular Endocrinology (155 abstracts)

Safety and efficiency of short-term glucocorticoid treatment in laryngological patients – pilot study

Lucyna Papierska 1 , Wiktor Miechowski 2 , Karolina Dżaman 2 & Wojciech Zgliczynski 1


1Centre of Postgraduate Medical Education, Department of Endocrinology, Warsaw, Poland; 2Centre of Postgraduate Medical Education, Department of Otolaryngology, Warsaw, Poland


Patients with chronic sinusitis with polyps are prepared for surgery (FESS) in one of two ways: through intranasal steroid therapy or oral preparation. The high-dose oral glucocorticoids are not often used in Poland, because of the due to the risk of developing side effects including pituitary-adrenal axis inhibition with the need for steroid cover during surgery. The 30 patients before FESS were randomly divided into two equal-sized groups. Patients in the first group received intranasal fluticasone propionate at a dose of 800 μg /day for 8 consecutive weeks before surgery. Patients in the second group received oral prednisone at a dose of 0.5 mg/kg/day for 7 days. The degree of polyposis assessed by sinus CT decreased statistically significantly only after treatment with oral steroid (13.14 (95%CI 8.95-15.92) vs. 8.0 (95%CI 4.05-10.59) P=0.000012 on a Lund-Mackay scale). There was no statistically significant difference in ACTH levels (14,73 (95%CI 11,85-19,49) vs. 21,09 (95%CI 12,28-41,08) and in morning cortisol levels before and after oral steroid treatment 1.41 (95%CI 8.44-14.20) vs. 8.16 (95%CI 6.69-14.2) P=0.39) and this effect did not differ from that observed after intranasal therapy. Electrolytes, glucose, and insulin levels also did not change significantly after this treatment. The operation was performed without hydrocortisone cover and no complications were observed. In conclusion, we have stated that our data confirmed the lack of inhibition of the pituitary-adrenal axis after short-term high-doses GCS therapy. We are planning further research in this area with the goal of introducing oral GCS into the standard preparation for FESS.

Volume 99

26th European Congress of Endocrinology

Stockholm, Sweden
11 May 2024 - 14 May 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.